Marketing Authorisation for Gliolan® granted in Jordan

photonamic GmbH & Co KG (Photonamic) are pleased to announce the approval of Gliolan® (5-ALA) in Jordan, marking a significant milestone as the first marketing authorisation for this product in the Middle East Region. This achievement has been made possible through our collaboration with Al Hilal Drug Store, one of the long-established pharmaceutical trading companies in Jordan since 1978.

The approval and upcoming launch of Gliolan® in Jordan has been made possible through Photonamic's long-standing partnership with Al Hilal Drug Store. This collaboration leverages Al Hilal's local expertise and distribution network, which is crucial for successfully introducing Gliolan® to the Jordanian market and potentially expanding to other Middle Eastern countries.

In preparation for the launch, essential steps are already in progress, including:

- *Training program for neurosurgeons*
- *Establishing an efficient supply chain*
- *Developing comprehensive stakeholder communications*

Dr. Ulrich Kosciessa, CEO of Photonamic; "We are very pleased to have Al Hilal as a valued partner in Jordan who will be able use their local expertise to successfully launch Gliolan®. We will ensure to support Al Hilal to achieve their goals. We look forward to seeing the benefits Gliolan® will have on the removal of malignant gliomas for both the patient and neurosurgeon."

Jordan has one of the most modern health systems in the region.
It`s healthcare sector is known for its adoption of advanced medical technologies, making it an ideal market for innovative products like Gliolan®.

Gliolan® in Jordan is indicated in adults for visualisation of malignant tissue during surgery for malignant glioma (WHO grade III and IV). Gliolan® is taken orally by the patient prior to surgery. In combination with a specialist magnification device and blue light source, Gliolan® fluoresces the malignant part of the tumour enabling the surgeon to make a distinction between malignant and normal tissue.

As Photonamic continues its geographic expansion, the success in Jordan could serve as a springboard for further growth in the Middle East region.

About photonamic GmbH & Co KG

photonamic is a German based company focused on the development and manufacturing of 5-ALA in various applications in the healthcare field. As a member of the SBI group with its parent company SBI ALApharma GmbH, the main achievement of photonamic to date is the development and registration of 5-ALA for the fluorescence-guided resection of glioblastoma which is marketed as Gliolan®, Gleolan™ or Alabel™ in Europe, United States, Canada, Japan, Australia and Korea. Within the group, photonamic and its affiliated companies in the US, Canada and Japan are diligently extending the development activities with 5-ALA even outside the field of photodynamic application, e.g. immune modulation in infectious diseases, food supplement and cosmetics.